• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Triple antithrombotic therapy in patients undergoing percutaneous coronary intervention: balancing between ischemia and bleeding.

作者信息

Koskinas Konstantinos C, Räber Lorenz

机构信息

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

出版信息

Cardiovasc Diagn Ther. 2017 Jun;7(Suppl 2):S128-S130. doi: 10.21037/cdt.2017.04.02.

DOI:10.21037/cdt.2017.04.02
PMID:28748165
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5509926/
Abstract
摘要

相似文献

1
Triple antithrombotic therapy in patients undergoing percutaneous coronary intervention: balancing between ischemia and bleeding.接受经皮冠状动脉介入治疗患者的三联抗栓治疗：缺血与出血之间的平衡
Cardiovasc Diagn Ther. 2017 Jun;7(Suppl 2):S128-S130. doi: 10.21037/cdt.2017.04.02.
2
Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.接受经皮冠状动脉介入治疗的心房颤动患者的抗栓策略
Curr Treat Options Cardiovasc Med. 2019 Feb 7;21(1):3. doi: 10.1007/s11936-019-0705-8.
3
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.接受经皮冠状动脉介入治疗的非瓣膜性心房颤动患者预防长期主要不良心血管事件的抗栓策略。
Expert Opin Pharmacother. 2017 Jun;18(9):875-883. doi: 10.1080/14656566.2017.1329822. Epub 2017 May 22.
4
Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation.使用三联抗栓治疗达到治疗性国际标准化比值（INR）范围的足够时间与药物洗脱支架植入术后的长期心血管事件和严重出血并发症无关。
J Cardiol. 2016 Dec;68(6):517-522. doi: 10.1016/j.jjcc.2015.10.019. Epub 2016 Mar 25.
5
Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range.三联抗栓治疗是发生大出血并发症的独立预测因素：治疗时间百分比分析。
Circ Cardiovasc Interv. 2013 Aug;6(4):444-51. doi: 10.1161/CIRCINTERVENTIONS.113.000179. Epub 2013 Aug 13.
6
Triple, dual, and single antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention.接受经皮冠状动脉介入治疗的心房颤动患者的三联、双联和单联抗栓治疗。
Cardiovasc Interv Ther. 2020 Jan;35(1):44-51. doi: 10.1007/s12928-019-00600-1. Epub 2019 Jul 8.
7
Triple antithrombotic therapy in patients with atrial fibrillation who have undergone percutaneous coronary intervention with stent implantation.经皮冠状动脉介入治疗术后伴心房颤动患者的三联抗栓治疗。
Am J Health Syst Pharm. 2012 Sep 1;69(17):1485-93. doi: 10.2146/ajhp110556.
8
Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.三联疗法：经皮冠状动脉介入治疗的心房颤动患者抗血栓治疗的综述。
J Cardiol. 2019 Jan;73(1):1-6. doi: 10.1016/j.jjcc.2018.09.001. Epub 2018 Oct 4.
9
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.经皮冠状动脉介入治疗的口服抗凝治疗心房颤动患者的抗血栓治疗：北美视角-2018 年更新。
Circulation. 2018 Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722.
10
The balance between anti-ischemic efficacy and bleeding risk of antithrombotic therapy in percutaneous coronary intervention: a Yin-Yang paradigm.经皮冠状动脉介入治疗中抗血栓治疗的抗缺血疗效与出血风险之间的平衡：一种阴阳范式。
J Invasive Cardiol. 2010 Jun;22(6):284-92.

本文引用的文献

1
Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者三联抗栓治疗的持续时间及预后
Cardiovasc Diagn Ther. 2017 Jun;7(Suppl 2):S66-S68. doi: 10.21037/cdt.2016.11.07.
2
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.经皮冠状动脉介入治疗（PCI）的房颤患者的出血预防。
N Engl J Med. 2016 Dec 22;375(25):2423-2434. doi: 10.1056/NEJMoa1611594. Epub 2016 Nov 14.
3
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.接受利伐沙班两种治疗策略或剂量调整口服维生素K拮抗剂治疗策略的冠状动脉内支架置入术房颤患者的再住院情况
Circulation. 2017 Jan 24;135(4):323-333. doi: 10.1161/CIRCULATIONAHA.116.025783. Epub 2016 Nov 14.
4
Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.接受经皮冠状动脉介入治疗的患者三联抗栓治疗的持续时间与结局。
JACC Cardiovasc Interv. 2016 Jul 25;9(14):1473-83. doi: 10.1016/j.jcin.2016.04.027.
5
Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial.药物洗脱支架置入术后需口服抗凝的患者三联治疗的持续时间：ISAR-TRIPLE 试验。
J Am Coll Cardiol. 2015 Apr 28;65(16):1619-1629. doi: 10.1016/j.jacc.2015.02.050.
6
2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).2014年欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南：欧洲心脏病学会（ESC）和欧洲心胸外科学会（EACTS）心肌血运重建特别工作组编写，欧洲经皮心血管介入协会（EAPCI）提供特别贡献。
Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29.
7
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS).急性冠状动脉综合征患者和/或接受经皮冠状动脉介入或瓣膜介入治疗的心房颤动患者的抗栓治疗管理：欧洲心脏病学会血栓形成工作组、欧洲心律协会（EHRA）、欧洲经皮心血管介入协会（EAPCI）和欧洲急性心脏护理协会（ACCA）的联合共识文件，得到心律学会（HRS）和亚太心律学会（APHRS）认可。
Eur Heart J. 2014 Dec 1;35(45):3155-79. doi: 10.1093/eurheartj/ehu298. Epub 2014 Aug 25.
8
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.口服抗凝治疗并行经皮冠状动脉介入治疗的患者中氯吡格雷联合或不联合阿司匹林的应用：一项开放标签、随机、对照试验。
Lancet. 2013 Mar 30;381(9872):1107-15. doi: 10.1016/S0140-6736(12)62177-1. Epub 2013 Feb 13.
9
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.新一代依维莫司洗脱支架与早期药物洗脱支架相比的极晚期冠状动脉支架血栓形成：一项前瞻性队列研究。
Circulation. 2012 Mar 6;125(9):1110-21. doi: 10.1161/CIRCULATIONAHA.111.058560. Epub 2012 Feb 1.
10
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.